Vitamin D and Lipid Profiles in Postmenopausal Women: A Meta-Analysis and Systematic Review of Randomized Controlled Trials

Liu, Wei-Ting; Wu, Zezhen; Zhu, Dan; Chen, Genben; Ge, Yan; Zhang, Shuo; Chen, Fengwu; Khan, Barkat Ali; Hou, Kaijian

doi:10.3389/fmolb.2021.799934

Cited by 10 publications

(9 citation statements)

References 49 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, elevated serum 25(OH)VD were associated with an increased level of HDL-C and TC, and lower serum 25(OH)VD were associated with higher TG and LDL-C levels. Many researchers have also reported similar results as our study ( 49 , 50 ). However, elevated serum 25(OH)VD were also associated with higher level of TC in our study, which might be owing to the participants in our study were diagnosed with different types of HL, which could lead to a selection bias, since the relationship between VD levels and serum levels of lipid profiles might be different according to various individual clinical statuses ( 5 , 51 , 52 ).…”

Section: Discussionsupporting

confidence: 91%

Association of serum total 25-hydroxy-vitamin D concentration and risk of all-cause, cardiovascular and malignancies-specific mortality in patients with hyperlipidemia in the United States

et al. 2022

View full text Add to dashboard Cite

BackgroundVitamin D (VD) plays an important role in decreasing the risk of adverse events for various metabolic diseases. However, for patients with hyperlipidemia, the relationship between the main VD storage within the body known as serum 25-hydroxy-VD [25(OH)VD] and the risk of all-cause, cardiovascular and malignancies-specific mortality is still unclear.Materials and methodsA total of 6740 participants above the age of 20 years with hyperlipidemia who completed the National Health and Nutrition Examination Survey (NHANES) between 2007 and 2016 and were followed up until 2019 were included in the study. The weighted Cox proportional hazards regression model and weighted competing risk regression model were used to evaluate the risk for all-cause, cardiovascular and malignancy-related mortality in relation to the serum 25(OH)VD. The model was adjusted according to age, gender, race, body mass index, lipids status, medication usage, the Charlson comorbidity index and healthy eating index. The last restricted cubic spline (RCS) method was used to present the relationship between hazard ratios (HR) associated with diverse cause-specified modalities and the serum 25(OH)VD levels.ResultsSerum 25(OH)VD was identified as an independent factor for mortality. Lower serum 25(OH)VD under the threshold of 25.6 and 25.2 ng/ml were significantly associated with a higher risk for all-cause and cardiovascular mortalities, respectively. However, no association was found between malignancy-specific mortality and serum 25(OH)VD.ConclusionSerum 25(OH)VD were identified as an independent factor associated with risks of all-cause and cardiovascular mortalities in patient with hyperlipidemia. Moreover, lower serum 25(OH)VD than 25.6 and 25.2 ng/mL were, respectively, associated with a gradual increase in a risk for all-cause and cardiovascular mortality in patients with hyperlipidemia, and therefore regular monitoring of VD levels and correction of VD deficiency is recommended in those patients.

show abstract

Section: Discussionsupporting

confidence: 91%

Association of serum total 25-hydroxy-vitamin D concentration and risk of all-cause, cardiovascular and malignancies-specific mortality in patients with hyperlipidemia in the United States

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The reduction of T-Chol and LDL-Chol levels observed in our study is similar to that obtained using a nutraceutical combination containing berberine, policosanol, and red yeast rice, drugs regularly used in the clinical management of patients with dyslipidemia [32]. In addition, the reduction in atherogenic lipids is similar to this observed in previous studies performed in adults and in children [33][34][35][36][37], but, of interest, none of these studies was performed in adult hypertensive patients, who are subjects at increased cardiovascular risk.…”

Section: Discussionsupporting

confidence: 90%

Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study

et al. 2022

View full text Add to dashboard Cite

The vitamin D and microRNA (miR) systems may play a role in the pathogenesis of cardiometabolic disorders, including hypertension. The HYPODD study was a double-blind placebo-controlled trial aiming to assess the effects of cholecalciferol treatment in patients with well-controlled hypertension and hypovitaminosis D (25OHD levels < 50 nmol/L). In addition to this clinical trial, we also evaluated the effects of cholecalciferol and calcitriol treatment on miR-21 expression in vivo and in vitro, respectively. Changes in the cardiovascular risk profiles were evaluated in HYPODD patients treated with cholecalciferol (C-cohort) or with placebo (P-cohort). The miR-21circulating levels were measured in four C-cohort patients and five P-cohort patients. In vitro, the miR-21 levels were measured in HEK-293 cells treated with calcitriol or with ethanol vehicle control. Cholecalciferol treatment increased 25OHD levels and reduced parathormone, total cholesterol, and low-density lipoprotein cholesterol levels in C-cohort patients, whereas no significant changes in these parameters were observed in P-cohort patients. The miR-21 circulating levels did not change in the C- or the P-cohort patients upon treatment. Calcitriol treatment did not affect miR-21 levels in HEK-293 cells. In conclusion, hypovitaminosis D correction ameliorated the cardiovascular risk profiles in hypertensive patients treated with cholecalciferol but did not influence the miR-21 expression.

show abstract

“…However, a vitamin D dose of >400 IU/day may slightly decrease LDL-C (WMD −1.89 mg/dL, 95% CI −2.47 to −1.31) [92]. Although to a lesser extent, these alterations in TG and HDL-C concentrations of postmenopausal women were also shown in another metaanalysis, but without any effect on LDL-C and TC (vitamin D dosage: 300-4000 IU/day) [93]. No data on baseline 25(OH)D concentrations were available from these two meta-analyses.…”

Section: Cardiovascular Risk Factorsmentioning

confidence: 82%

Vitamin D, Menopausal Health and COVID-19: Critical Appraisal of Current Data

Anagnostis

Livadas

Goulis

et al. 2023

JCM

View full text Add to dashboard Cite

Inconsistency exists across studies conducted in postmenopausal women regarding the effect of vitamin D deficiency (VDD) and supplementation on several aspects of menopausal health, such as fractures, vasomotor symptomatology, cardiovascular disease (CVD), cancer and infections, including coronavirus disease 2019 (COVID-19). The aim of this review is to critically summarize the evidence provided by observational studies and randomized controlled trials (RCTs) of vitamin D supplementation in postmenopausal women with VDD. Observational studies have found that VDD is associated with an increased risk of falls and fractures after the menopause. VDD also has a negative effect on menopausal symptomatology. VDD, especially its severe form, is associated with an increased risk of CVD risk factors and CVD events. VDD is associated with increased risk and mortality from several cancer types and risk of infections. The evidence from RCTs regarding the effect of vitamin D supplementation on falls, fractures, menopausal symptoms, cardiovascular disease, cancer and infections is not robust. Thus, skeletal health may benefit only when vitamin D is co-administered with calcium, especially in those ≥70 years old and with severe VDD. There is no evidence of a favorable effect on menopausal symptoms or risk of CVD or cancer, except for a modest reduction in cancer-related mortality. Inconsistency still exists regarding its effect on infection risk, disease severity and mortality due to COVID-19.

show abstract

Vitamin D and Lipid Profiles in Postmenopausal Women: A Meta-Analysis and Systematic Review of Randomized Controlled Trials

Cited by 10 publications

References 49 publications

Association of serum total 25-hydroxy-vitamin D concentration and risk of all-cause, cardiovascular and malignancies-specific mortality in patients with hyperlipidemia in the United States

Association of serum total 25-hydroxy-vitamin D concentration and risk of all-cause, cardiovascular and malignancies-specific mortality in patients with hyperlipidemia in the United States

Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study

Vitamin D, Menopausal Health and COVID-19: Critical Appraisal of Current Data

Contact Info

Product

Resources

About